# GenFleet Therapeutics (Shanghai)

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genfleet-therapeutics-shanghai

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.genfleet.com
- Total disclosed funding: $168M
- Latest round: Series C (Dec 31, 2021)
- Investors on record: 27

## About

Founded in 2017 and based in Shanghai, China, GenFleet Therapeutics specializes in drug development focusing on oncology and immunology. ?In September 2025,?GenFleet Therapeutics (Shanghai) Inc. ?raised?HKD 1.82 billion?in an IPO, selling?89.24 million shares?at?HKD 20.39 per share at Hong Kong Stock Exchange under the ticker symbol "2595".
GenFleet Therapeutics (Shanghai) Inc. provides oncology and immunology. The company's pipeline includes small and large molecule therapeutics targeting unvalidated clinical indications. The company product, Daberit® (Furazepirase), is the first KRAS G12C inhibitor approved in China and the third globally. 
The company generates revenue by researching and developing innovative therapeutic products, focusing on solid tumors, hematological malignancies, and autoimmune diseases and other related products.

## Funding rounds

- Series C, Dec 31, 2021, $79M — CDH Investments, Panlin Capital, Huagai Capital, Qiaojing Capital, Baidu Ventures, DYEE Capital, HM Capital, Lake Bleu Capital, SUXIN, ShangJin Capital, Wenzhou Investment, Cherami Investment Group, ABC International Capital
- Series B, Jan 27, 2021 — CDH Investments, NLVC, Panlin Capital, HM Capital, Linden Asset Group, ShangJin Capital
- Series B, Mar 8, 2020, $57M — CDH Investments, BOCOM International Asset Management, Panlin Capital, Shanghai Jianyi Private Equity Fund Management, HighLight Capital, South China Venture Capital, Shenzhen Capital Real Estate Fund, Lake Ventures, Lake Bleu Capital, Guoxin Sichuang Investment Management, R&G PharmaStudies Co., Ltd.
- Series A, Nov 30, 2018, $17M — Shijiazhuang Pharma, Shanghai Jianyi Private Equity Fund Management, Ally Bridge Group, HighLight Capital, TF Capital, Hidragon Capital
- Angel, Nov 30, 2017, $15M — HighLight Capital, TF Capital, Hidragon Capital

## Investors

- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Angel, Series A, Series B
- TF Capital — Angel, Series A
- Hidragon Capital (https://capitalatlas.ai/funds/hidragon-capital) — Angel, Series A
- Shijiazhuang Pharma — Series A
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series A, Series B
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series A
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series B, Series C
- BOCOM International Asset Management (https://capitalatlas.ai/funds/bocom-international-asset-management) — Series B
- Panlin Capital (https://capitalatlas.ai/funds/panlin-capital) — Series B, Series C
- South China Venture Capital (https://capitalatlas.ai/funds/south-china-venture-capital) — Series B
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series B
- Lake Ventures — Series B
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series B, Series C
- Guoxin Sichuang Investment Management (https://capitalatlas.ai/funds/guoxin-sichuang-investment-management) — Series B
- R&G PharmaStudies Co., Ltd. — Series B
- NLVC (https://capitalatlas.ai/funds/nlvc) — Series B
- HM Capital (https://capitalatlas.ai/funds/hm-capital) — Series B, Series C
- Linden Asset Group — Series B
- ShangJin Capital — Series B, Series C
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series C
- Qiaojing Capital (https://capitalatlas.ai/funds/qiaojing-capital) — Series C
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series C
- DYEE Capital (https://capitalatlas.ai/funds/dyee-capital) — Series C
- SUXIN — Series C
- Wenzhou Investment (https://capitalatlas.ai/funds/wenzhou-investment) — Series C
- Cherami Investment Group (https://capitalatlas.ai/funds/cherami-investment-group) — Series C
- ABC International Capital (https://capitalatlas.ai/funds/abc-international-capital) — Series C